SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation
CRSP 51.59-1.1%Dec 2 3:59 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Jibacoa who wrote (2865)2/9/2001 5:47:43 PM
From: Biomaven  Read Replies (1) of 52153
 
I have to say that I've been bitten a couple of times on testing companies (in my early biotech investing days) and have now learnt my lesson.

Doctors don't particularly like POC tests, perhaps because of reimbursement issues, perhaps because of the hassle factor.

Doctors also don't like non-traditional tests of any sort, even assuming they work well.

Even when they do sell, margins for these tests are low - nothing at all like the money-printing margins you see in a good drug.

One caveat- if someone does come up with a good, reliable, non-messy and non-invasive screening test for colon cancer, I guess they will do well.

NMPS intermittently pops on exciting-sounding news before it goes down when their sales disappoint (which is always). Some day, I suppose, they might make good.

Peter
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News